
|Articles|August 28, 2012
PODCAST: Dr. Goldfischer on OAB
PODCAST Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Advertisement
PODCAST: Dr. Goldfischer on OAB
Efficacy and safety study comparing Oxybutynin 3% topical gel vs. placebo in adults with Overactive Bladder Syndrome.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
2
Published data show rPFS benefit with lutetium Lu 177 vipivotide tetraxetan in mHSPC
3
Elizabeth Nally, MBBS, on decision regret and toxicity perception with adjuvant pembrolizumab
4
Optimizing care for men with overactive bladder, with Keith Xavier, MD
5








